Stock CIPLA CIPLA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cipla Limited

Equities

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:47 2024-04-26 am EDT 		5-day change 1st Jan Change
1,409 INR +0.21% Intraday chart for Cipla Limited +4.71% +13.07%
Apr. 24 Indian Equities End Higher Midweek as Iran-Israel Conflict Subsides MT
Apr. 19 Cipla Limited Receives Order from the GST Authority CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 426,134 340,917 657,346 821,377 726,839 1,137,701 - -
Enterprise Value (EV) 1 463,108 359,042 658,708 810,334 716,397 1,081,876 1,055,259 1,027,456
P/E ratio 27.9 x 22.1 x 27.4 x 32.7 x 26 x 27.6 x 25.2 x 22.6 x
Yield 0.57% 0.71% 0.61% 0.49% 0.94% 0.61% 0.65% 0.72%
Capitalization / Revenue 2.6 x 1.99 x 3.43 x 3.77 x 3.19 x 4.41 x 4.06 x 3.71 x
EV / Revenue 2.83 x 2.1 x 3.44 x 3.72 x 3.15 x 4.19 x 3.77 x 3.35 x
EV / EBITDA 15 x 11.2 x 15.5 x 17.8 x 14.3 x 17.2 x 15.5 x 13.6 x
EV / FCF 34.8 x 14.4 x 21.1 x 29.1 x 29.9 x 32.4 x 27.4 x 23.9 x
FCF Yield 2.87% 6.95% 4.74% 3.43% 3.35% 3.09% 3.65% 4.18%
Price to Book 2.7 x 2.16 x 3.59 x 3.94 x 3.11 x 4.26 x 3.74 x 3.29 x
Nbr of stocks (in thousands) 805,699 806,235 806,460 806,814 807,151 807,367 - -
Reference price 2 528.9 422.8 815.1 1,018 900.5 1,409 1,409 1,409
Announcement Date 5/22/19 5/15/20 5/14/21 5/10/22 5/12/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 163,624 171,320 191,596 217,633 227,531 257,973 279,909 306,971
EBITDA 1 30,973 32,060 42,524 45,528 50,270 62,962 68,052 75,404
EBIT 1 17,710 20,313 31,848 35,008 38,549 52,639 56,579 62,830
Operating Margin 10.82% 11.86% 16.62% 16.09% 16.94% 20.4% 20.21% 20.47%
Earnings before Tax (EBT) 1 20,791 21,782 32,901 34,933 40,384 57,277 62,394 69,672
Net income 1 15,277 15,465 24,049 25,168 28,019 41,265 44,967 50,412
Net margin 9.34% 9.03% 12.55% 11.56% 12.31% 16% 16.06% 16.42%
EPS 2 18.93 19.16 29.79 31.17 34.69 51.11 55.83 62.48
Free Cash Flow 1 13,311 24,957 31,255 27,818 23,971 33,440 38,487 42,964
FCF margin 8.13% 14.57% 16.31% 12.78% 10.54% 12.96% 13.75% 14%
FCF Conversion (EBITDA) 42.98% 77.84% 73.5% 61.1% 47.69% 53.11% 56.56% 56.98%
FCF Conversion (Net income) 87.13% 161.37% 129.97% 110.53% 85.55% 81.04% 85.59% 85.23%
Dividend per Share 2 3.000 3.000 5.000 5.000 8.500 8.634 9.195 10.14
Announcement Date 5/22/19 5/15/20 5/14/21 5/10/22 5/12/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: Maart 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 51,687 46,064 55,044 55,198 54,789 52,603 53,752 58,285 58,101 57,393 63,289 64,681 64,992 62,574 69,303
EBITDA 1 12,309 7,962 13,459 12,262 12,310 7,497 11,434 13,023 14,076 11,737 14,939 15,121 15,951 13,891 -
EBIT 1 9,824 5,110 10,848 9,731 9,835 4,594 8,889 10,030 11,354 8,275 12,547 12,819 13,101 11,194 13,861
Operating Margin 19.01% 11.09% 19.71% 17.63% 17.95% 8.73% 16.54% 17.21% 19.54% 14.42% 19.82% 19.82% 20.16% 17.89% 20%
Earnings before Tax (EBT) 1 10,215 5,437 9,955 9,958 10,541 4,478 9,746 11,004 12,181 7,454 13,746 13,757 13,933 12,446 -
Net income 1 7,482 4,134 7,147 7,114 7,286 3,621 6,864 7,889 8,010 5,256 9,957 9,743 10,517 9,088 -
Net margin 14.47% 8.97% 12.98% 12.89% 13.3% 6.88% 12.77% 13.54% 13.79% 9.16% 15.73% 15.06% 16.18% 14.52% -
EPS 2 9.260 5.120 8.850 8.800 9.020 4.480 8.500 9.770 9.920 6.510 12.33 12.53 12.86 11.25 -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/29/21 5/14/21 8/5/21 10/26/21 1/25/22 5/10/22 7/29/22 11/4/22 1/25/23 5/12/23 7/26/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: Maart 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 36,974 18,125 1,363 - - - - -
Net Cash position 1 - - - 11,043 10,443 55,826 82,442 110,245
Leverage (Debt/EBITDA) 1.194 x 0.5654 x 0.032 x - - - - -
Free Cash Flow 1 13,311 24,957 31,255 27,818 23,971 33,440 38,487 42,964
ROE (net income / shareholders' equity) 10.4% 10.1% 14.1% 12.9% 12.7% 16.2% 15.4% 15.2%
ROA (Net income/ Total Assets) 6.53% 6.49% 9.85% 9.63% 9.91% 12.7% 11.9% 12%
Assets 1 234,120 238,129 244,072 261,266 282,821 325,660 376,671 418,648
Book Value Per Share 2 196.0 196.0 227.0 258.0 290.0 330.0 377.0 429.0
Cash Flow per Share 2 21.00 38.00 46.50 41.20 40.10 58.40 62.70 67.70
Capex 1 3,601 5,728 6,297 5,441 11,829 10,659 10,786 10,796
Capex / Sales 2.2% 3.34% 3.29% 2.5% 5.2% 4.13% 3.85% 3.52%
Announcement Date 5/22/19 5/15/20 5/14/21 5/10/22 5/12/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cipla Limited

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
34
Last Close Price
1,409 INR
Average target price
1,453 INR
Spread / Average Target
+3.10%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
-4.29% 4.71B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CIPLA Stock
  4. Financials Cipla Limited